This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hande, K. R. Articles by Wilding, G. Search for Related Content PubMed PubMed Citation Articles by Hande, K. R. Articles by Wilding, G.

Phase I and Pharmacokinetic Study of Prinomastat, a Matrix Metalloprotease Inhibitor

¹ Vanderbilt University School of Medicine, Nashville, Tennessee; ² Agouron Pharmaceuticals, A Pfizer Company, La Jolla, California; and ³ University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin

Purpose: Prinomastat is a matrix metalloprotease (MMP) inhibitor with selectivity for MMPs 2, 3, 9, 13, and 14. Inhibition of these MMPs has been postulated to block tumor invasion and metastasis. This Phase I, dose-escalation study was designed to evaluate the acute and chronic toxicities of various doses of prinomastat and to determine prinomastat pharmacokinetics.

Experimental Design: Seventy-five patients with advanced cancer were given 1, 2, 5, 10, 25, 50, or 100 mg prinomastat orally twice daily until tumor progression or development of significant toxicities. Prinomastat pharmacokinetics were measured on day 29 of therapy.

Results: The primary toxicities identified were joint and muscle-related pain, which were generally reversible with treatment rest and/or dose reduction. No dose-limiting toxicities were noted within the first 4 weeks of treatment, but grade 2–3 arthralgias and myalgias were noted 2–3 months after initiation of therapy in >25% of patients at doses >25 mg twice a day. The frequency and severity of symptoms were dose related. Plasma prinomastat concentrations greater than the K_i for MMPs 2 and 9 were achieved at all of the dose levels.

Conclusions: Doses of 5–10 mg bid were recommended for additional trials, because this dose range was well tolerated for a treatment duration of at least 3 months and achieves trough plasma concentrations 10–100-fold greater than the K_i (in vitro inhibition constant) for the targeted MMPs (2 and 9).

This article has been cited by other articles:

				J. Liu, M. Zhan, J. A.F. Hannay, P. Das, S. V. Bolshakov, D. Kotilingam, D. Yu, A. F. Lazar, R. E. Pollock, and D. Lev Wild-type p53 Inhibits Nuclear Factor-{kappa}B-Induced Matrix Metalloproteinase-9 Promoter Activation: Implications for Soft Tissue Sarcoma Growth and Metastasis Mol. Cancer Res., November 1, 2006; 4(11): 803 - 810. [Abstract] [Full Text] [PDF]

				A. Y. Savinov, D. V. Rozanov, and A. Y. Strongin Mechanistic insights into targeting T cell membrane proteinase to promote islet {beta}-cell rejuvenation in type 1 diabetes FASEB J, September 1, 2006; 20(11): 1793 - 1801. [Abstract] [Full Text] [PDF]

				A. Y. Savinov, D. V. Rozanov, V. S. Golubkov, F. S. Wong, and A. Y. Strongin Inhibition of Membrane Type-1 Matrix Metalloproteinase by Cancer Drugs Interferes with the Homing of Diabetogenic T Cells into the Pancreas J. Biol. Chem., July 29, 2005; 280(30): 27755 - 27758. [Abstract] [Full Text] [PDF]

				A. Kruger, M. J.E. Arlt, M. Gerg, C. Kopitz, M. M. Bernardo, M. Chang, S. Mobashery, and R. Fridman Antimetastatic Activity of a Novel Mechanism-Based Gelatinase Inhibitor Cancer Res., May 1, 2005; 65(9): 3523 - 3526. [Abstract] [Full Text] [PDF]